Enhancement of IgE-mediated histamine release from human basophils by viruses: role of interferon

S Ida, J J Hooks, R P Siraganian, A L Notkins, S Ida, J J Hooks, R P Siraganian, A L Notkins

Abstract

Human leukocytes maintained in culture are induced to release histamine when exposed to ragweed antigen E or anti-IgE. Leukocyte cultures incubated with virus (i.e. HSV-1, Influenza A, and Adeno-1) but not exposed to ragweed antigen E or anti-IgE fail to release histamine. If, however, leukocyte cultures are first exposed to virus and then to ragweed antigen E or anti-IgE, significant enhancement of histamine release occurs. Both infectious and inactivated virus enhance histamine release and the degree of enhancement is related to the concentration of virus and the length of the incubation. Tissue culture fluid harvested 8 h after exposure of leukocytes to virus contains a soluble factor which is capable of enhancing histamine release when added to fresh leukocyte cultures. This factor has all the properties of interferon including species specificity and cannot be dissociated from the antiviral activity of interferon. Moreover, both known inducers of interferon (poly I:poly C) and standard preparations of interferon are capable of enhancing histamine release. The enhancement of histamine release by interferon represents a new biological role for interferon.

References

    1. J Immunol Methods. 1975 Jun;7(2-3):283-90
    1. Am Rev Respir Dis. 1976 Feb;113(2):131-9
    1. Am J Dis Child. 1962 Oct;104:330-4
    1. Am Rev Respir Dis. 1976 Feb;113(2):149-53
    1. Infect Immun. 1976 Nov;14(5):1172-8
    1. J Clin Microbiol. 1976 Dec;4(6):479-85
    1. Immunology. 1970 Nov;19(5):831-42
    1. J Immunol. 1972 Apr;108(4):1000-8
    1. J Clin Invest. 1972 Jul;51(7):1927-31
    1. J Clin Invest. 1972 Nov;51(11):2941-7
    1. Fed Proc. 1974 Nov;33(11):2256-62
    1. Clin Pediatr (Phila). 1966 Oct;5(10):586-92
    1. Proc Soc Exp Biol Med. 1969 Apr;130(4):1333-6
    1. Ann Allergy. 1970 Feb;28(2):43-9
    1. Chest. 1973 Apr;63:Suppl:44S-48S
    1. J Pediatr. 1973 Apr;82(4):578-90
    1. JAMA. 1974 Jan 21;227(3):292-8
    1. Ann Allergy. 1974 Sep;33(3):145-9
    1. Br Med J. 1972 Aug 5;3(5822):323-7
    1. Anal Biochem. 1974 Feb;57(2):383-94
    1. Pediatr Clin North Am. 1969 Feb;16(1):67-83
    1. Annu Rev Pharmacol. 1975;15:177-89
    1. J Immunol. 1975 Dec;115(6):1572-6
    1. J Allergy. 1965 Nov-Dec;36(6):558-63
    1. Br Med J. 1969 Nov 8;4(5679):321-5
    1. Prog Allergy. 1975;19:60-121
    1. J Immunol. 1976 Sep;117(3):1049-53
    1. J Immunol. 1977 Feb;118(2):679-84

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi